The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study Name on
ClinicalTrials.gov (link is external)
A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
Study Drug GLPG2222
Type of Study Drug CFTR modulator
Study Title A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation
Study Phase 2a
Study Sponsor Galapagos

Link on
clinicaltrials.gov (link is external)

https://clinicaltrials.gov/ct2/show/NCT03045523

Participating ECFS-CTN sites Please contact ecfs-ctn@uzleuven.be for most recent sitelist
Age 18 Years to 99 Years